アプタマー アフェレシス 核酸医薬の開発|タグシクス・バイオ株式会社

News Release

2022.9.8
News Release CAGE Bio, TAGCyx and PeptiStar announce execution of a license agreement for development and commercialization of TAGX-0003 for the treatment of immunodermatology diseases mediated by the IFN-γ pathway
2022.3.23
News Release TAGCyx secured a grant funding from ‘Support Program for Orphan drug prior to the Designation’ of Japan Agency for Medical Research and Development (AMED).
2021.7.7
News Release TAGCyx raises approximately 210 million JPY
2021.3.22
News Release Prof. Shinsuke Sando at THE UNIVERSITY OF TOKYO and TAGCyx ANNOUNCES THE RESEARCH COLLABORATION of THE TECHNOLOGICAL IMPROVEMENT OF XENOLIGO®
2021.3.5
News Release TAGCyx announces execution of worldwide exclusive supply of proprietary artificial Ds amidite and patent license agreement with Otsuka Chemical Co., Ltd.
2021.2.19
News Release Prof. Taiichi Sakamoto at CHIBA INSTITUTE TECHNOLOGY and TAGCyx ANNOUNCES THE RESEARCH COLLABORATION of THE STRUCTURAL ANALYSIS OF XENOLIGO®
2020.11.25
News Release SBI Pharmaceuticals and TAGCyx ANNOUNCES THE RESEARCH AND DEVELOPMENT COLLABORATION OF INOVATIVE CANCER THERAPY
2020.11.17
News Release Showa Denko Materials and the Drug Development Startup TAGCyx Sign a Commissioned Development Agreement on Regenerative Medicine Technologies
2020.9.18
News Release TAGCyx announces a research collaboration with CAGE Bio Inc. for autoimmune skin diseases.
2020.5.5
News Release TAGCyx raises approximately 200 million JPY
2020.2.19
News Release TAGCyx and GC Pharma has entered into collaborative research and development for conducting various pre-clinical studies of TAGX-0004
2019.12.25
News Release TAGCyx receives milestone payment for collaborative research with HEALIOS K.K.